Press Release | Mon Sep 24, 2012 8:03am EDT

Catalyst Pharmaceutical Partners Announces Commencement of CPP-109 Investigator-Sponsored Study in Patients With Treatment Refractory Tourette's Disorder

* Reuters is not responsible for the content in this press release.